Basic characteristics and treatment regimens in people with type 2 diabetes in the International Diabetes Management Practices Study (IDMPS)

HANCU N; BAIK SH; FERREIRA S; GAGLIARDINO JJ; CHAN J; ASCHNER P; RAMACHANDRAN A; TWIGG S; ILKOVA H

Washington DC

Congreso; 66th Scientific Sessions of the American Diabetes Association; 2006

American Diabetes Association

The IDMPS is a multinational observational study that aims to gather data that reflect current care practices of people with diabetes in different areas of the world and to evaluate the compliance with international care guidelines. Data are being collected from type 2 diabetic patients (¡Ã18 years) in 1-year cycles (a 2-week cross-sectional period followed by a 9-month longitudinal period) for 5 years. Data from the first cross-sectional period are currently available from 7543 people (48% men) in 11 countries in Eastern Europe, Asia, and Latin America. The mean age was 58¡¾11 years, mean BMI 27¡¾5 kg/m¡ù2 (men: 26¡¾4 kg/m¡ù2, women: 27¡¾5 kg/m¡ù2) and mean disease duration 8 years. Mean HbA¡ø1c was 7.7¡¾1.75% and 38% of people had an HbA¡ø1c <7%. Among people with HbA¡ø1c <7%, 4% were treated with diet and exercise only, 77% with oral antihyperglyemic agents (OHAs) alone and 19% with insulin ¡¾ OHAs. A regimen of diet and exercise was reported in 3% of people (mean HbA¡ø1c of 6.9¡¾1.67%). OHAs alone were used by 67% of people (mean HbA¡ø1c of 7.4¡¾1.60%). Insulin ¡¾ OHAs were used by 16% of people (average insulin dose 36 IU, mean HbA¡ø1c of 8.3¡¾1.89%). Mean FBG (laboratory) was 152¡¾60 mg/dL. Mean systolic/diastolic blood pressure was 135/81 mmHg. Target treatment values were obtained for LDL (<100 mg/dL) in 34% of people, HDL (>40 mg/dL) in 64% of people, and triglycerides (<150 mg/dL) in 48% of people. As can be seen, despite the evidence provided by the UKPDS and the recommendations of the ADA, the majority of people did not achieve the recommended treatment goals for HbA¡ø1c and FBG. It is thus apparent that more efficient guidance and education be made available to improve treatment outcomes in people with type 2 diabetes world wide.